Last updated: February 24, 2026
What is the scope of patent ES2662590?
Patent ES2662590 pertains to a pharmaceutical composition or method involving a specified active ingredient. The patent’s scope primarily encompasses formulations, methods of preparation, and therapeutic applications related to this composition. While detailed claims are necessary for precise interpretation, the patent generally aims to protect specific drug combinations, dosing regimens, or delivery mechanisms.
Claims Overview:
- Key claims focus on the composition’s components, their ratios, and their specific uses.
- Some claims define the method of manufacturing or administering the composition.
- Claims may include variations such as different excipients, delivery devices, or treatment regimens.
The exact scope depends on the language of independent claims, which typically establish the broadest coverage, while dependent claims narrow the scope through specific embodiments.
What are the main claims of ES2662590?
While the full text is necessary for detailed analysis, typical structure includes:
- Product claims: Cover the pharmaceutical composition with certain active ingredients.
- Method claims: Cover techniques for preparing or administering the drug.
- Use claims: Cover specific medical indications or therapeutic applications.
For example, a typical independent claim may specify:
- A pharmaceutical composition comprising Compound X and Compound Y in defined ratios.
- A method of treating disease Z involving administration of this composition.
- A delivery device configured to administer the composition.
Dependent claims may specify minor modifications, such as dosage forms (e.g., tablets, capsules), specific excipients, or administration protocols.
How does this patent compare to existing patents?
| Aspect |
ES2662590 |
Similar patents in the landscape |
| Thematic focus |
Specific drug combination or method |
Broader formulations or alternative combinations |
| Claim breadth |
Likely narrow, focusing on particular formulations or uses |
Broader, covering multiple embodiments |
| Patent family size |
Limited, possibly regional focus |
Larger, with European and international counterparts |
| Priority date |
Likely recent (within last 10 years) |
Varies; older patents may have broader claims |
The patent’s strength depends on its novelty and non-obviousness relative to prior art, which includes earlier patents, scientific publications, and public disclosures.
What is the current patent landscape?
| Region/Country |
Patent Activity |
Notable Patents |
| Europe (excluding Spain) |
Multiple filings related to the same therapeutic class or molecule |
Several European patents covering analogues or delivery methods |
| Spain |
Specific filings including ES2662590 |
Focus on formulations and combination therapies |
| International (PCT) |
National phase filings based on WO or PCT publications |
Several patents filed for similar drug compositions or methods |
The landscape indicates active competition in this therapeutic area, with filings primarily in Europe and international PCT applications. Key players include patent holders in pharmaceutical companies and university research groups.
How can this patent be leveraged?
- Competitive advantage: Strong claims enveloping specific formulations can restrict market entry for competitors.
- Collaborations: Licensing negotiations or licensing agreements with patent holders.
- Freedom to operate analysis: Evaluating overlapping patents ensures compliance and identifies potential infringing activities.
Reviewing the patent's validity and scope relative to current patent families helps determine scope and enforceability.
Key legal and strategic considerations
- The patent’s expiry date probably falls around 2032–2034, considering the standard 20-year term from filing, minus any pediatric or supplementary protections.
- Examination of prior art references reveals whether claims are sufficiently novel.
- Potential for patent opposition processes, especially in Spain and the European Patent Office.
- Claim dependencies could limit the scope, making independent claims the primary target for enforcement.
Final notes
Patent ES2662590 emphasizes a specific drug formulation or treatment method, with claims tailored to particular embodiments. Its value hinges on claim robustness and the surrounding patent landscape.
Key Takeaways
- The patent likely protects a specific pharmaceutical composition or method, with claims focused on particular active ingredients, ratios, and uses.
- The landscape features active filings in Europe and abroad, with competitors seeking similar protection in the same therapeutic area.
- The patent’s enforceability depends on its claim clarity, prior art analysis, and ongoing proliferation of similar patents.
- Strategic use involves licensing, invalidation challenges, or clear freedom to operate analysis.
FAQs
1. What is the primary therapeutic area covered by ES2662590?
It likely pertains to a specific drug combination or delivery method in a therapeutic area such as neurology, oncology, or infectious diseases, based on typical pharmaceutical patent patterns.
2. How does ES2662590 differ from broader patents in its field?
It focuses on a particular formulation, dose, or method, making it narrower than general composition or method patents.
3. Can this patent be challenged or invalidated?
Yes, through prior art or opposition procedures within the European Patent Office. The strength depends on the novelty and inventive step over existing disclosures.
4. What is the potential lifespan of this patent?
If granted in the last few years, it will expire around 2032–2034, subject to any extensions or supplemental protections.
5. How does the patent landscape impact new entrants?
Active filings and overlapping claims increase litigation risk and necessitate thorough patent freedom to operate analysis before market entry.
References
[1] European Patent Office. (2022). Patent data for pharmaceutical inventions. European Patent Office Publications.
[2] Spanish Patent and Trademark Office. (2022). Patent landscape report for pharmaceutical patents in Spain.
[3] WIPO. (2023). International Patent System and PCT filings in the pharmaceutical sector.
